Highlights
- •Leucocytoclastic vasculitis is associated with immune-checkpoint inhibitors therapy.
- •Thrombocytopenic purpura is the main differential diagnosis.
- •Steroids and hydroxychloroquine are an effective and safe therapy.
Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to European Journal of Internal MedicineAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- The blockade of immune checkpoints in cancer immunotherapy.Nat Rev Cancer. 2012; 12: 252-264
- A systematic review of immune-related adverse event reporting in clinical trials of immune checkpoint inhibitors.Ann Oncol. 2015; 26: 1824-1829
- Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies.Ann Oncol. 2015; 26 ([mdv383])
- Rheumatic manifestations among cancer patients treated with immune checkpoint inhibitors.Autoimmun Rev. 2018; 17: 284-289
- Vasculitis associated with immune checkpoint inhibitors - A systematic review.Clin Rheumatol. 2018;
- Idiopathic thrombocytopenic purpura and autoimmune neutropenia induced by prolonged use of nivolumab in Hodgkin's lymphoma.Ann Oncol. 2017; 28: 1675-1676
Article info
Publication history
Published online: August 01, 2018
Accepted:
July 25,
2018
Received in revised form:
July 17,
2018
Received:
July 11,
2018
Identification
Copyright
© 2018 European Federation of Internal Medicine. Published by Elsevier B.V. All rights reserved.
